Curcumin Formulations and Trials: What’s New in Neurological Diseases
Curcumin’s pharmacological properties and its possible benefits for neurological diseases and dementia have been much debated. In vitro experiments show that curcumin modulates several key physiological pathways of importance for neurology. However, in vivo studies have not always matched expectatio...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-11-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/25/22/5389 |
| _version_ | 1797547567807987712 |
|---|---|
| author | Stella Gagliardi Carlo Morasso Polychronis Stivaktakis Cecilia Pandini Veronica Tinelli Aristides Tsatsakis Davide Prosperi Miriam Hickey Fabio Corsi Cristina Cereda |
| author_facet | Stella Gagliardi Carlo Morasso Polychronis Stivaktakis Cecilia Pandini Veronica Tinelli Aristides Tsatsakis Davide Prosperi Miriam Hickey Fabio Corsi Cristina Cereda |
| author_sort | Stella Gagliardi |
| collection | DOAJ |
| description | Curcumin’s pharmacological properties and its possible benefits for neurological diseases and dementia have been much debated. In vitro experiments show that curcumin modulates several key physiological pathways of importance for neurology. However, in vivo studies have not always matched expectations. Thus, improved formulations of curcumin are emerging as powerful tools in overcoming the bioavailability and stability limitations of curcumin. New studies in animal models and recent double-blinded, placebo-controlled clinical trials using some of these new formulations are finally beginning to show that curcumin could be used for the treatment of cognitive decline. Ultimately, this work could ease the burden caused by a group of diseases that are becoming a global emergency because of the unprecedented growth in the number of people aged 65 and over worldwide. In this review, we discuss curcumin’s main mechanisms of action and also data from in vivo experiments on the effects of curcumin on cognitive decline. |
| first_indexed | 2024-03-10T14:45:54Z |
| format | Article |
| id | doaj.art-7ff15ad0572143e5a3d72b2a8861cfec |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-10T14:45:54Z |
| publishDate | 2020-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-7ff15ad0572143e5a3d72b2a8861cfec2023-11-20T21:21:45ZengMDPI AGMolecules1420-30492020-11-012522538910.3390/molecules25225389Curcumin Formulations and Trials: What’s New in Neurological DiseasesStella Gagliardi0Carlo Morasso1Polychronis Stivaktakis2Cecilia Pandini3Veronica Tinelli4Aristides Tsatsakis5Davide Prosperi6Miriam Hickey7Fabio Corsi8Cristina Cereda9Genomic and Post Genomic Unit, IRCCS Mondino Foundation, 27100 Pavia, ItalyIstituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, ItalyMedical School, University of Crete, 70013 Heraklion, GreeceGenomic and Post Genomic Unit, IRCCS Mondino Foundation, 27100 Pavia, ItalyIstituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, ItalyMedical School, University of Crete, 70013 Heraklion, GreeceIstituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, ItalyDepartment of Pharmacology, Institute of Biomedicine and Translational Medicine, University of Tartu, 50411 Tartu, EstoniaIstituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, ItalyGenomic and Post Genomic Unit, IRCCS Mondino Foundation, 27100 Pavia, ItalyCurcumin’s pharmacological properties and its possible benefits for neurological diseases and dementia have been much debated. In vitro experiments show that curcumin modulates several key physiological pathways of importance for neurology. However, in vivo studies have not always matched expectations. Thus, improved formulations of curcumin are emerging as powerful tools in overcoming the bioavailability and stability limitations of curcumin. New studies in animal models and recent double-blinded, placebo-controlled clinical trials using some of these new formulations are finally beginning to show that curcumin could be used for the treatment of cognitive decline. Ultimately, this work could ease the burden caused by a group of diseases that are becoming a global emergency because of the unprecedented growth in the number of people aged 65 and over worldwide. In this review, we discuss curcumin’s main mechanisms of action and also data from in vivo experiments on the effects of curcumin on cognitive decline.https://www.mdpi.com/1420-3049/25/22/5389curcuminneurological diseasesnanoformulationclinical trials |
| spellingShingle | Stella Gagliardi Carlo Morasso Polychronis Stivaktakis Cecilia Pandini Veronica Tinelli Aristides Tsatsakis Davide Prosperi Miriam Hickey Fabio Corsi Cristina Cereda Curcumin Formulations and Trials: What’s New in Neurological Diseases Molecules curcumin neurological diseases nanoformulation clinical trials |
| title | Curcumin Formulations and Trials: What’s New in Neurological Diseases |
| title_full | Curcumin Formulations and Trials: What’s New in Neurological Diseases |
| title_fullStr | Curcumin Formulations and Trials: What’s New in Neurological Diseases |
| title_full_unstemmed | Curcumin Formulations and Trials: What’s New in Neurological Diseases |
| title_short | Curcumin Formulations and Trials: What’s New in Neurological Diseases |
| title_sort | curcumin formulations and trials what s new in neurological diseases |
| topic | curcumin neurological diseases nanoformulation clinical trials |
| url | https://www.mdpi.com/1420-3049/25/22/5389 |
| work_keys_str_mv | AT stellagagliardi curcuminformulationsandtrialswhatsnewinneurologicaldiseases AT carlomorasso curcuminformulationsandtrialswhatsnewinneurologicaldiseases AT polychronisstivaktakis curcuminformulationsandtrialswhatsnewinneurologicaldiseases AT ceciliapandini curcuminformulationsandtrialswhatsnewinneurologicaldiseases AT veronicatinelli curcuminformulationsandtrialswhatsnewinneurologicaldiseases AT aristidestsatsakis curcuminformulationsandtrialswhatsnewinneurologicaldiseases AT davideprosperi curcuminformulationsandtrialswhatsnewinneurologicaldiseases AT miriamhickey curcuminformulationsandtrialswhatsnewinneurologicaldiseases AT fabiocorsi curcuminformulationsandtrialswhatsnewinneurologicaldiseases AT cristinacereda curcuminformulationsandtrialswhatsnewinneurologicaldiseases |